SCHEMBL666528

SCHEMBL666528

Cc1ccc(C(=O)NC2=CC(=O)C3OC3C2O)c(O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARK7 Q99497 1/20 0.50
PLG P00747 3/20 0.43
KLK1 P06870 2/20 0.43
KLK6 Q92876 2/20 0.43
F2 P00734 1/20 0.42
F10 P00742 1/20 0.42
PLAU P00749 1/20 0.42
PLAT P00750 1/20 0.42
KDR P35968 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
TAS1R2 Q8TE23 1/20 0.41
ALOX15 P16050 1/20 0.40
STAT3 P40763 1/20 0.40
RAB9A P51151 4/20 0.40
LMNA P02545 2/20 0.40
HSD17B10 Q99714 2/20 0.40
TSHR P16473 1/20 0.40
PIK3CG P48736 1/20 0.39
NPC1 O15118 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL666050 0.91 PARK7 (0.50) PARK7F2F10PLAUPLAT
SCHEMBL665039 0.86 PARK7 (0.50) PARK7PLGF2F10PLAU
SCHEMBL666281 0.85 PARK7 (0.55) PARK7TAS1R3TAS1R1ALOX15RAB9A
SCHEMBL169409 0.85 PARK7 (0.48) PARK7RAB9AHSD17B10NPC1TP53
SCHEMBL665007 0.85 PARK7 (0.48) PARK7PLGKLK1KLK6ALOX15
Dehydroxymethylepoxyquinomicin SCHEMBL1669417 0.84 PARK7 (0.54) PARK7RAB9ALMNAHSD17B10TSHR
Dehydroxymethylepoxyquinomicin SCHEMBL1671089 0.84 PARK7 (0.54) PARK7RAB9ALMNAHSD17B10TSHR
Dehydroxymethylepoxyquinomicin SCHEMBL14504317 0.84 PARK7 (0.54) PARK7RAB9ALMNAHSD17B10TSHR
Dehydroxymethylepoxyquinomicin SCHEMBL14491796 0.84 PARK7 (0.54) PARK7RAB9ALMNAHSD17B10TSHR
SCHEMBL116427 0.83 PARK7 (0.48) PARK7RAB9ANPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046357-A1 Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) PROFECTUS BIOSCIENCES, INC. (US) 2012-02-23 US claimed
US-20120046357-A1 Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) PROFECTUS BIOSCIENCES, INC. (US) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046357-A1 Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) NFKBIA, IKBKB, NFKB1 PARK7 3384/4885PLG 3148/4885KLK1 443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.